BioXcel Therapeutics, Inc. (BTAI)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Neuroscience and Immuno-oncology Drugs	1.38M	Log In
Neuroscience and Immuno-oncology Drugs Growth	268.00%	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	1.38M	Log In
United States Growth	268.00%	Log In